Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Rallybio Corp (RLYB)

Rallybio declares $82.7 million special cash distribution tied to Avenzo merger

Neutral Impact 4 of 5 shareholder Written later

Rallybio's board declared an estimated $82.7 million special cash distribution, or about $13.56 per share, payable to holders of record as of November 5, 2026, in connection with its planned merger with Avenzo Therapeutics. Payment depends on stockholder approval at the November 4, 2026 annual meeting, and the actual amount may be higher or lower than the estimate. Shareholders buying during the due bill period (November 4 through November 6, 2026) will receive the distribution, while sellers will not.

Key points

  • Estimated cash distribution of $82.7 million, or $13.56 per share, based on 6,378,168 shares and equivalents outstanding as of October 21, 2026
  • Record Date November 5, 2026; ex-dividend date expected November 6, 2026; distribution scheduled for November 13, 2026
  • Payment conditioned on Required Company Stockholder Vote at the annual meeting at 10:00 a.m. Eastern Time on November 4, 2026
  • Merger closing expected on or about November 6, 2026

The filing

CompanyRallybio Corp (RLYB)
Form8-K, current report
Filed with the SECOct 26, 2026, 4:53 PM ET
Accession number0001193125-26-432114

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.